Therefore, exploring the underlying mechanism of the CDK4/6 pathway in cancer cells and the interactions of CDK4/6 inhibitors in combination therapy could help identify new therapeutic strategies for ccRCC. This evidence concerns the gene CDK4 and nonpapillary renal cell carcinoma.